



## Bydureon BCise® (exenatide extended-release) – Expanded indication

- On July 23, 2021, the [FDA approved](#) AstraZeneca's [Bydureon BCise \(exenatide extended-release\)](#), as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus (T2DM).
  - Bydureon BCise was previously approved for this indication in adults only.
- Limitations for use for Bydureon BCise include:
  - Not recommended as first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of the rat thyroid C-cell tumor findings to humans.
  - Not indicated for use in patients with type 1 diabetes mellitus.
  - Bydureon BCise is an extended-release formulation of exenatide and should not be used with other products containing the active ingredient exenatide.
  - Has not been studied in patients with a history of pancreatitis. Other antidiabetic therapies should be considered in patients with a history of pancreatitis.
- The approval of Bydureon BCise for the expanded indication was based on a 24-week, randomized, double-blind, placebo-controlled study in 82 patients age 10 to 17 years with T2DM treated with diet and exercise alone or in combination with a stable dose of oral antidiabetic agents and/or insulin. The primary endpoint was the change in HbA1c from baseline to week 24.
  - The mean change in HbA1c at week 24 was -0.25 and 0.45 for Bydureon and placebo, respectively. The difference from placebo was -0.71 (95% CI: -1.42, 0;  $p < 0.05$ ).
- Bydureon BCise carries a boxed warning for risk of thyroid C-cell tumors.
- The recommended dose of Bydureon BCise for all patients is 2 mg subcutaneously once every 7 days (weekly). The dose can be administered at any time of day, with or without meals.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.